Elekta scores two VMAT installs

Radiation therapy device and informatics developer Elekta reported that it has placed two of its volumetric modulated arc therapy (VMAT) systems in Europe and that the technology is in clinical use.

The company said that The Royal Marsden Hospital in Sutton, U.K., and General Hospital in Vienna, Austria, is using the VMAT product to treat patients at their facilities.

With VMAT technology, the target is continuously radiated while the source of the beam is rotated around the patient in single or multiple arcs. By simultaneously controlling gantry position, gantry speed, leaves of the multi-leaf collimator, collimator angle and dose rate, a highly conformal dose distribution is created in less time than with other techniques, according to Elekta. Utilizing VMAT, a treatment session typically can be conducted in five minutes or less, including true 3D imaging to secure the location of the target, Elekta said.

The technology is pending 510(k) regulatory clearance in the United States.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.